Advertisement


Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy

ASH 2025

Advertisement

Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction chemotherapy in fit patients with newly diagnosed acute myeloid leukemia (AML)and could challenge the current treatment standard (Abstract 6). 



Related Videos

Leukemia

Aaron Logan, MD, PhD, on Relapsed/Refractory B-Cell ALL: Real-World Data on Brexucabtagene Autoleucel and Transplant

Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed or refractory Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (ALL) (Abstract 516). 

Myelodysplastic Syndromes

Mikkael Sekeres, MD, MS, on MDS and Exposure to Agent Orange

Mikkael Sekeres, MD, MS, Chief, Division of Hematology and Professor of Medicine at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presents findings from a new study that connects exposure to the herbicide Agent Orange to earlier and more severe cases of myelodysplastic syndromes (MDS). Researchers concluded that exposure is associated with younger age at MDS diagnosis, ultimate MDS diagnosis, genetic complexity of MDS, increased risk of disease progression, and with Black race (Abstract 5626). 

Myelodysplastic Syndromes

Valeria Santini, MD, on Imetelstat for Lower-Risk MDS: Long-Term Outcomes From the IMerge Trial

The telomerase inhibitor imetelstat was approved for the treatment of certain patients with lower-risk myelodysplastic syndromes (MDS) based on the results of the phase III IMerge trial. Valeria Santini, MD, of the University of Florence, provides updates on secondary endpoints, including overall and progression-free survival; progression to acute myeloid leukemia; safety; and long-term outcomes by subgroups of interest in IMerge, as well as ad hoc outcomes, including overall survival by response (Abstract 2074). 

Myelodysplastic Syndromes

Amer Zeidan, MBBS, on Lower-Risk MDS: Treatment-Emergent Cytopenias and Clinical Response

Amer Zeidan, MBBS, of Yale School of Medicine, discusses findings from an analysis of the IMerge trial, which explored the possible association between imetelstat-related cytopenias and hemoglobin increasea measure linked to red blood cell transfusion independence achievement—in patients with lower-risk myelodysplastic syndromes (MDS) (Abstract 490). 

Multiple Myeloma

Jack Khouri, MD, on Multiple Myeloma: Burixafor and Propranolol With G-CSF Before Transplant

Jack Khouri, MD, of Cleveland Clinic, describes the findings of a phase II trial which investigated the safety and efficacy of burixafor (GPC-100), a potent and selective small -molecule antagonist of CXCR4, and propranolol with granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPC) in patients with multiple myeloma. Researchers aimed to boost the bone marrow HPC niche and optimize mobilization in patients with multiple myeloma eligible for autologous hematopoietic cell transplant (Abstract 1050). 

Advertisement

Advertisement




Advertisement